CHU Amiens - Groupe Hospitalier Sud
- Address
- 1 1 rond-point du Professeur Cabrol, 80054 Amiens, France
CHU Amiens - Groupe Hospitalier Sud
CHU Amiens - Groupe Hospitalier Sud is a specialized medical research facility engaged in advanced oncology research, with particular emphasis on rare and challenging tumor types affecting both adult and pediatric populations. The center demonstrates expertise in developing innovative therapeutic approaches for complex cancerous conditions requiring specialized neurological and ophthalmological interventions.
- Adult brainstem gliomas with focus on diffuse, non-enhancing subtypes and infiltrative progression patterns
- Pediatric retinoblastoma management with emphasis on conservative treatment strategies and vision preservation
- Chemotherapy protocols including temozolomide-based regimens and intra-arterial chemotherapy (IAC) techniques
The research center's commitment to conservative treatment approaches is particularly evident in their retinoblastoma studies, where they evaluate both intra-arterial chemotherapy for local disease control and visual function outcomes based on WHO criteria. Their work with non-enhancing brainstem gliomas addresses a critical gap in treatment options for patients with infiltrative disease progression, exploring first-line chemotherapy alternatives to traditional radiotherapy approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Amiens - Groupe Hospitalier Sud
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of mFOLFIRINOX Versus Platinum-Etoposide in First-Line Chemotherapy for Metastatic Grade 3 Gastroenteropancreatic Neuroendocrine Carcinoma | Centre Hospitalier Universitaire De Dijon | Phase II | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etoposide | 3 | Unknown | 2021-03-25 | 2024-10-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.